A Phase 3 interventional study of Brivaracetam (ucb 34714) in Epilepsy, sponsored by UCB Pharma. Completed at 153 sites in 26 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-08-17.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one has the largest enrollment, is one of 4 that started in 2005, is one of 21 in phase 3, and was the 2nd registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2005.
This study's enrollment of 853 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 4th largest by enrollment of the 116 interventional ones that give a count, is one of 8 that started in 2005, is one of 74 in phase 3, and was the 14th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial, evaluating the long-term safety and tolerability of brivaracetam, will give subjects suffering from epilepsy, who may have benefited from brivaracetam, the opportunity to continue the treatment. The study will also evaluate the maintenance of efficacy over time of brivaracetam for subjects with partial onset seizures (POS)/primary generalized seizures (PGS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Flexible dosing, can up and down titrate as needed.
Drug: Brivaracetam (ucb 34714)
10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.
Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE)
Treatment-emergent adverse events (TEAEs) were defined as those events which started on or after the date of first dose of investigational medicinal product (IMP), or events in which severity worsened on or after the date of first dose of study medication. The event does not necessarily have a causal relationship with that treatment or usage.
Time frame: From Entry Visit until Last Visit (up to 162 months)
Percentage of Participants Who Withdrew Due to an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant or trial participant that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.
Time frame: From Entry Visit until Last Visit (up to 162 months)
Percentage of Participants With at Least One Serious Adverse Event (SAE)
A serious adverse event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires in patient hospitalization or prolongation of existing hospitalization * Is a congenital anomaly or birth defect * Is an infection that requires treatment parenteral antibiotics * Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.
Time frame: From Entry Visit until Last Visit (up to 162 months)
Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days During the Evaluation Period
The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28. Baseline values for seizure frequency were calculated based on the seizure diary data collected during the baseline period of the previous double-blind studies: N01114 \[NCT00175929\], N01252 \[NCT00490035\] and N01254 \[NCT00504881\].
Time frame: From Entry Visit until Last Visit (up to 162 months)
Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period
The percent change from the previous study baselines, in Partial Onset Seizure (POS) (Type I) frequency per 28 days is defined as: (the value at the previous study baselines) minus (the value at each time-points during the evaluation period) divided by the value at the previous study baselines. Baseline values for seizure frequency were calculated based on the seizure diary data collected during the baseline period of the previous double-blind studies: N01114 \[NCT00175929\], N01252 \[NCT00490035\] and N01254 \[NCT00504881\].
Time frame: From Entry Visit until Last Visit (up to 162 months)
Responder Rate in POS (Type I) Frequency Over the Evaluation Period
A responder is defined as a participant with a ≥ 50% reduction in seizure frequency from the Baseline Period of the previous study. Baseline values for seizure frequency were calculated based on the seizure diary data collected during the baseline period of the previous double-blind studies: N01114 \[NCT00175929\], N01252 \[NCT00490035\] and N01254 \[NCT00504881\].
Time frame: From Entry Visit until Last Visit (up to 162 months)
The study started to enroll patients in September 2005 and concluded in May 2019.
| Milestone | Brivaracetam |
|---|---|
| Started | 853 |
| Completed | 234 |
| Not completed | 619 |
| Withdrew: Death | 19 |
| Withdrew: Adverse event | 81 |
| Withdrew: Lack of efficacy | 354 |
| Withdrew: Lost to follow-up | 17 |
| Withdrew: Subject choice | 98 |
| Withdrew: Lack of compliance | 8 |
| Withdrew: Patient cannot record seizures | 1 |
| Withdrew: Sponsor decision | 17 |
| Withdrew: Vigabatrin intake | 1 |
| Withdrew: Suicidal behaviour | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Seizure - free | 4 |
| Withdrew: Administrative reason | 1 |
| Withdrew: Pregnancy | 1 |
| Withdrew: Patient's request | 2 |
| Withdrew: Treating physiciant's choice | 1 |
| Withdrew: Moved overseas | 1 |
| Withdrew: Loss of job and economic burden | 1 |
| Withdrew: Site was closed | 9 |
| Withdrew: Patient went to prison | 1 |
Treatment-emergent adverse events (TEAEs) were defined as those events which started on or after the date of first dose of investigational medicinal product (IMP), or events in which severity worsened on or after the date of first dose of study medication. The event does not necessarily have a causal relationship with that treatment or usage.
| Percentage of participants | Brivaracetam (SS) |
|---|---|
| Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) | 84.4 |
An AE is any untoward medical occurrence in a participant or trial participant that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.
| Percentage of participants | Brivaracetam (SS) |
|---|---|
| Percentage of Participants Who Withdrew Due to an Adverse Event (AE) | 11.6 |
A serious adverse event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires in patient hospitalization or prolongation of existing hospitalization * Is a congenital anomaly or birth defect * Is an infection that requires treatment parenteral antibiotics * Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.
| Percentage of participants | Brivaracetam (SS) |
|---|---|
| Percentage of Participants With at Least One Serious Adverse Event (SAE) | 29.4 |
The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28. Baseline values for seizure frequency were calculated based on the seizure diary data collected during the baseline period of the previous double-blind studies: N01114 \[NCT00175929\], N01252 \[NCT00490035\] and N01254 \[NCT00504881\].
| Seizures per 28 days | Brivaracetam (POS Efficacy) |
|---|---|
| Baseline | 8.4 (5.0 to 16.1) |
| On Treatment | 4.9 (2.1 to 10.8) |
The percent change from the previous study baselines, in Partial Onset Seizure (POS) (Type I) frequency per 28 days is defined as: (the value at the previous study baselines) minus (the value at each time-points during the evaluation period) divided by the value at the previous study baselines. Baseline values for seizure frequency were calculated based on the seizure diary data collected during the baseline period of the previous double-blind studies: N01114 \[NCT00175929\], N01252 \[NCT00490035\] and N01254 \[NCT00504881\].
| Percent change | Brivaracetam (POS Efficacy) |
|---|---|
| Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period | 43.1 (9.9 to 71.5) |
A responder is defined as a participant with a ≥ 50% reduction in seizure frequency from the Baseline Period of the previous study. Baseline values for seizure frequency were calculated based on the seizure diary data collected during the baseline period of the previous double-blind studies: N01114 \[NCT00175929\], N01252 \[NCT00490035\] and N01254 \[NCT00504881\].
| Percentage of participants | Brivaracetam (POS Efficacy) |
|---|---|
| Responder Rate in POS (Type I) Frequency Over the Evaluation Period | 43.6 |
Collected over From Entry Visit until Last Visit (up to 162 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brivaracetam (SS) | 19/853 (2.2%) | 248/853 (29.1%) | 569/853 (66.7%) |
| Event | Brivaracetam (SS) |
|---|---|
| ConvulsionNervous system disorders | 36/853 |
| EpilepsyNervous system disorders | 11/853 |
| Head injuryInjury, poisoning and procedural complications | 10/853 |
| Status epilepticusNervous system disorders | 10/853 |
| PneumoniaInfections and infestations | 9/853 |
| MyoclonusNervous system disorders | 9/853 |
| Grand mal convulsionNervous system disorders | 8/853 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 7/853 |
| Suicidal ideationPsychiatric disorders | 7/853 |
| SepsisInfections and infestations | 6/853 |
| Event | Brivaracetam (SS) |
|---|---|
| HeadacheNervous system disorders | 186/853 |
| NasopharyngitisInfections and infestations | 157/853 |
| DizzinessNervous system disorders | 123/853 |
| ConvulsionNervous system disorders | 112/853 |
| FatigueGeneral disorders | 84/853 |
| DiarrhoeaGastrointestinal disorders | 78/853 |
| Back painMusculoskeletal and connective tissue disorders | 77/853 |
| Urinary tract infectionInfections and infestations | 75/853 |
| SomnolenceNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 73/853 |
| InsomniaPsychiatric disorders | 71/853 |
Baseline Characteristics refer to the Safety Set which consisted of all participants who took at least 1 dose of study medication.
| Age, Categorical(Participants) | Brivaracetam |
|---|---|
| <=18 years | 14 |
| Between 18 and 65 years | 827 |
| >=65 years | 12 |
| Age, Continuous(years) | Brivaracetam |
|---|---|
| Mean | 37.5 ± 11.8 |
| Sex: Female, Male(Participants) | Brivaracetam |
|---|---|
| Female | 418 |
| Male | 435 |
| Race/Ethnicity, Customized(Participants) | Brivaracetam |
|---|---|
| White | 721 |
| Black | 2 |
| Asian | 123 |
| Other | 7 |
Showing the first 100 of 153 sites across 26 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2005 to primary completion in May 2019, 164 months.
Results were first posted in Jul 2020, 1 year 2 months after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 164 months is above that.
Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam